Compare NNDM & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNDM | VSTM |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | 468 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.4M | 470.7M |
| IPO Year | 2015 | 2011 |
| Metric | NNDM | VSTM |
|---|---|---|
| Price | $1.91 | $5.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,437,000.00 | $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 77.30 | ★ 209.14 |
| 52 Week Low | $1.31 | $4.01 |
| 52 Week High | $2.32 | $11.25 |
| Indicator | NNDM | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 52.38 |
| Support Level | $1.47 | $5.48 |
| Resistance Level | $2.11 | $6.79 |
| Average True Range (ATR) | 0.09 | 0.38 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 83.87 | 45.34 |
Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.